When you think of the life span of a pair of glasses, there are likely two scenarios that pop into mind. Perhaps your prescription changed or maybe they broke. But say you’re amazing at caring for your glasses and your doctor says you don’t have changes to your vision that require you to get a new prescription, there is still an important aspect of your glasses you should keep up to date—your lenses.
Do lens coatings or additions break down over time?
“Coatings, just like anything else in the world has wear and tear, and they’re not going to last forever,” said VSP network doctor Nichole Moos, OD.
Wait, what’s a coating and why do I need it?
Coatings and additions, also known as lens enhancements, are an optional feature for your prescription lenses that are designed to improve your overall experience with your glasses. Not only do they help with glare and providing comfortable vision, they can protect your lenses from visible scratches that reduce your ability to see. They can also be water and oil resistant, as well as easier to clean. Common lens enhancement options include anti-reflective (AR) coatings, light-reactive, and blue light reduction. Having a lens enhancement or coating added to your lenses will optimize your vision, but it’s important to remember that a higher-quality AR coating will perform better, which will help to extend the life of the coating and the lenses.
There are several choices when it comes to enhancements, and an eye doctor can explain which options will benefit you the most. Your vision plan typically provides savings on different lens enhancements too.
According to Dr. Moos, lens enhancements and coatings can last anywhere from a year to about two years. With a higher-quality enhancement or coating and proper care, you can greatly increase the shelf-life of your lenses.
Watch Dr. Moos describe the signs that it’s time to update your lens coatings.
Consult with your eye doctor on what lens enhancements and coatings are right for you and when you need to replace them. Use our Find a Doctor tool for a quick and easy way to locate your nearest VSP network provider.
Don’t have a vision care plan? Check out all the available individual plans to meet your eye care needs.
If you have a general eye-related question, be sure to comment below or post to social media with hashtag #AskAnEyeDoc.
Disclaimer: Information received through VSP Vision Care’s social media channels is for informational purposes only and does not constitute medical advice, medical recommendations, diagnosis or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.
Editas Medicine , a company developing gene-editing treatments, has received authorization from the US Food and Drug Administration to launch a clinical trial for its emerging CRISPR/Cas9 therapy for people with a mutation in the gene CEP290, which causes Leber congenital amaurosis 10 (LCA10). LCA causes severe vision loss or blindness at birth. Known as EDIT-101, the treatment will be evaluated in a Phase 1/2, dose-escalation clinical trial. The company expects to enroll 10 to 20 patients. Further details and contact information for the study will be listed soon at www.clinicaltrials.gov . EDIT-101 targets a specific mutation, “c.2991+1655A>G” in intron 26, of the CEP290 gene. Editas has earned a $25 million milestone payment from Allergan as part of a drug-development alliance. “We are very pleased with this historic milestone in the treatment of inherited retinal diseases,” says Stephen Rose, PhD, chief scientific officer, Foundation Fighting Blindness. “EDIT-101 is the fi...
Written by Dr. David Evans Last modified on September 6, 2018 An article I wrote back in April described a National Bureau of Economic Research study that concluded cataract surgery patients have a life expectancy 1.8 years longer than people with cataracts who do not undergo surgery. Much of that piece focused on the finding that people, who have vision diminished by cataracts, are less likely to be active, and more likely to suffer accidental falls and related injuries. As a follow-on, a new study published in JAMA Ophthalmology suggests an even stronger link between cataract surgery and mortality risk. About the Study The genesis of this study was something completely different than evaluating effects of cataract vision loss. Its original purpose was to evaluate the effects of hormone therapy and dietary changes in postmenopausal women. That study was cut short once it was determined that hormone therapy increased the risk of vascular events. Although the hormone therapy aspect ...
ProQR, a biotech company in the Netherlands, ha s reported vision improvements for patients in a Phase 1/2 clinical trial for QR-110 , a therapy for people with Leber congenital amaurosis 10 (LCA10), which is caused by the p.Cys998X mutation in the CEP290 gene. The mutation is estimated to affect about 2,000 people in the Western world. The company reported that 60 percent of su bjects in the trial demonstrated improvements in visual acuity and their ability to navigate a mobility course . The treatment was also safe for patients. As a result of the encouraging interim results, ProQR has concluded the Phase 1/2 trial and plans to move the treatment into a Phase 2/3 clinical trial. Ten people were treated in the Phase 1/2 study. Results from the interim analy sis were presented on September 5, 2018, at the Retinal Degeneration 2018 meeting in Killarney, Ireland , by principal investigator Artur Cideciyan , PhD , research professor of ophthalmology at the Scheie Eye Ins...
Comments
Post a Comment